Match!
Alfredo Perales-Puchalt
Wistar Institute
50Publications
15H-index
748Citations
Publications 50
Newest
Published in Nature Communications11.88
John D. Lueck10
Estimated H-index: 10
(UR: University of Rochester),
Jae Seok Yoon (Cystic Fibrosis Foundation)+ -3 AuthorsPaul B. McCray71
Estimated H-index: 71
(UI: University of Iowa)
Premature termination codons (PTCs) are responsible for 10–15% of all inherited disease. PTC suppression during translation offers a promising approach to treat a variety of genetic disorders, yet small molecules that promote PTC read-through have yielded mixed performance in clinical trials. Here we present a high-throughput, cell-based assay to identify anticodon engineered transfer RNAs (ACE-tRNA) which can effectively suppress in-frame PTCs and faithfully encode their cognate amino acid. In ...
Published on Jul 1, 2019in Immunology4.15
Alfredo Perales-Puchalt15
Estimated H-index: 15
,
Elizabeth K. Duperret6
Estimated H-index: 6
+ 6 AuthorsMegan C. Wise9
Estimated H-index: 9
Published on May 24, 2019in Vaccine3.27
Krzysztof Wojtak1
Estimated H-index: 1
,
Krzysztof Wojtak2
Estimated H-index: 2
+ 0 AuthorsDavid B. Weiner79
Estimated H-index: 79
Infectious diseases are linked to 15%–20% of cancers worldwide. Among them, Epstein–Barr virus (EBV) is an oncogenic herpesvirus that chronically infects over 90% of the adult population, with over 200,000 cases of cancer and 150,000 cancer-related deaths attributed to it yearly. Acute EBV infection can present as infectious mononucleosis, and lead to the future onset of multiple cancers, including Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and gastric carcinoma. Many of these...
Published on Apr 18, 2019in JCI insight
Alfredo Perales-Puchalt15
Estimated H-index: 15
,
Elizabeth K. Duperret6
Estimated H-index: 6
+ 9 AuthorsMegan C. Wise9
Estimated H-index: 9
Published on Feb 1, 2019in Molecular Therapy8.40
Alfredo Perales-Puchalt15
Estimated H-index: 15
(Wistar Institute),
Krzysztof Wojtak2
Estimated H-index: 2
(Wistar Institute)
+ 6 AuthorsDavid B. Weiner79
Estimated H-index: 79
(Wistar Institute)
Ovarian cancer presents in 80% of patients as a metastatic disease, which confers it with dismal prognosis despite surgery and chemotherapy. However, it is an immunogenic disease, and the presence of intratumoral T cells is a major prognostic factor for survival. We used a synthetic consensus (SynCon) approach to generate a novel DNA vaccine that breaks immune tolerance to follicle-stimulating hormone receptor (FSHR), present in 50% of ovarian cancers but confined to the ovary in healthy tissues...
Published on Feb 1, 2019in Cancer immunology research8.62
Elizabeth K. Duperret6
Estimated H-index: 6
(Wistar Institute),
Alfredo Perales-Puchalt15
Estimated H-index: 15
(Wistar Institute)
+ 6 AuthorsDavid B. Weiner79
Estimated H-index: 79
(Wistar Institute)
T-cell recognition of cancer neoantigens is important for effective immune-checkpoint blockade therapy, and an increasing interest exists in developing personalized tumor neoantigen vaccines. Previous studies utilizing RNA and long-peptide neoantigen vaccines in preclinical and early-phase clinical studies have shown immune responses predominantly driven by MHC class II CD4 + T cells. Here, we report on a preclinical study utilizing a DNA vaccine platform to target tumor neoantigens. We showed t...
Published on Jan 2, 2019in OncoImmunology5.33
Alfredo Perales-Puchalt15
Estimated H-index: 15
(Wistar Institute),
Nikolaos Svoronos13
Estimated H-index: 13
(Wistar Institute)
+ 8 AuthorsJose R. Conejo-Garcia36
Estimated H-index: 36
ABSTRACTOvarian cancer is frequently diagnosed as peritoneal carcinomatosis. Unlike other tumor locations, the peritoneal cavity is commonly exposed to gut-breaching and ascending genital microorganisms and has a unique immune environment. IL-33 is a local cytokine that can activate innate and adaptive immunity. We studied the effectiveness of local IL-33 delivery in the treatment of cancer that has metastasized to the peritoneal cavity. Direct peritoneal administration of IL-33 delayed the prog...
Published on Jan 1, 2019in Oncotarget
Alfredo Perales-Puchalt15
Estimated H-index: 15
,
Elizabeth K. Duperret6
Estimated H-index: 6
+ 1 AuthorsDavid B. Weiner79
Estimated H-index: 79
// Alfredo Perales-Puchalt 1 , Elizabeth K. Duperret 1 , Kar Muthumani 1 and David B. Weiner 1 1 Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA Correspondence to: David B. Weiner, email: weiner@Wistar.org Keywords : immunotherapy; cancer; immune checkpoints; DMAb; monoclonal antibody Received: December 13, 2018 Accepted: December 16, 2018 Published: January 01, 2019 Abstract Checkpoint inhibitors (CPI) have revolutionized the treatment of many solid tumors. However...
Published on Dec 1, 2018in Clinical Cancer Research8.91
Elizabeth K. Duperret6
Estimated H-index: 6
(Wistar Institute),
Shujing Liu16
Estimated H-index: 16
(UPenn: University of Pennsylvania)
+ 9 AuthorsJian Yan30
Estimated H-index: 30
Purpose:Cancer/testis antigens have emerged as attractive targets for cancer immunotherapy. Clinical studies have targeted MAGE-A3, a prototype antigen that is a member of the MAGE-A family of antigens, in melanoma and lung carcinoma. However, these studies have not yet had a significant impact due to poor CD8+ T cell immunogenicity, platform toxicity, or perhaps limited target antigen availability. In this study we develop an improved MAGE-A immunogen with cross-reactivity to multiple family me...
12345